Xoclave Dry Syrup is a combination antibiotic formulation containing Amoxycillin 200 mg and Clavulanic Acid 28.5 mg per dose, designed for oral administration. Amoxycillin, a broad-spectrum penicillin antibiotic, inhibits bacterial cell wall synthesis, leading to cell lysis and death, while Clavulanic Acid acts as a beta-lactamase inhibitor, preventing enzymatic degradation of Amoxycillin by resistant bacterial strains. This synergistic combination enhances the efficacy against beta-lactamase-producing pathogens, including various Gram-positive and Gram-negative bacteria. Xoclave Dry Syrup is indicated for the treatment of respiratory tract infections, otitis media, sinusitis, urinary tract infections, skin and soft tissue infections, and dental infections caused by susceptible organisms. The dry syrup formulation is particularly suitable for pediatric patients and those with difficulty swallowing tablets. Dosage and duration of therapy should be determined by the severity of infection and patient-specific factors, including age and renal function. It is essential to complete the prescribed course to prevent resistance development. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and vomiting. Hypersensitivity reactions may occur in penicillin-sensitive individuals. Use with caution in patients with a history of allergy to beta-lactam antibiotics. Consult a healthcare professional before use.